MedTrace Logo

Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial Protocol

NCT03125824 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-02-14

No results posted yet for this study

Summary

To further evaluate accelerated fading resulting from additional treatment sessions of Soliton AWD as accessory to laser in tattoo reduction treatment.

Conditions

  • Tattooing

Interventions

DEVICE

Soliton Acoustic Wave Device

Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser

Sponsors & Collaborators

  • MedSource LLC

    collaborator OTHER

  • Soliton

    lead INDUSTRY

Principal Investigators

  • Christopher Cappelli, MD · Soliton

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-13
Primary Completion
2018-05-23
Completion
2018-09-25
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03125824 on ClinicalTrials.gov